Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka - LARVOL DELTA

Neoadjuvant cadonilimab plus chemotherapy for locally advanced gastric/gastroesophageal junction cancer: A single-arm, phase II trial. (ASCO 2026) - P2 | " Eligible patients with locally advanced G/GEJ cancer (cT3-4a N+ M0) were enrolled and treated with 3 cycles of SOX chemotherapy (oxaliplatin 130mg/m2, IV, d1; S-1 40-60 mg, PO, bid, d1-d14; q21d) plus cadonilimab (10mg/Kg IV, d1, q21d), followed by radical gastrectomy with D2 lymphadenectomy... Based on the encouraging pCR rate, survival outcome and manageable safety in this study, cadonilimab plus SOX chemotherapy is a promising neoadjuvant treatment option for patients with locally advanced gastric cancer. Moreover, targeting stromal and myeloid components may be necessary to unlock the full therapeutic potential of immune checkpoint blockade."

Clinical • Metastases • P2 data • Fibrosis • Gastric Cancer • Oncology • Solid Tumor • Thrombocytopenia • CD8

A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma (clinicaltrials.gov) - P2 | N=34 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

New P2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Sintilimab Combined With Albumin-Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review. (PubMed, Clin Case Rep) - "For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD-1 inhibitor with albumin-bound paclitaxel and S-1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with favorable performance status and MDT-supported indications, as pathological complete remission appears to be attainable in this context."

Journal • Gastric Cancer • Oncology • Solid Tumor

Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: A multicenter, open-label phase 2 study. (ASCO 2026) - P2 | "The data from this trial supports the favorable and efficacy of nab-paclitaxel plus S-1 for locally advanced pancreatic cancer, as well as the possibility of converting unresectable disease into surgically resectable disease."

Clinical • Metastases • P2 data • Leukopenia • Neutropenia • Oncology • Pancreatic Cancer • Solid Tumor

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. (PubMed, Nat Commun) - P2 | "In this single-armed, phase II, exploratory trial (NCT03878472), we evaluate the efficacy of a combination of ICI (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin) for neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer...The toxicity and post-surgery complications are limited. These data support further validation of ICI- and antiangiogenesis-based neoadjuvant/conversion therapy in large randomized trials and provide candidate biomarkers."

Checkpoint block • Checkpoint inhibition • IO biomarker • Journal • Metastases • Tumor mutational burden • Gastric Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • MSI • PD-L1 • RREB1 • TMB

Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV) (ESMO 2023) - P2/3 | "Methods Pts with T3-4aN+M0 were randomized 1:1 to SOXRC (C 200 mg IV D1 + R 250 mg PO QD D1-21 + oxaliplatin 130 mg/m2 IV D1 + S-1 PO BID D1-14, Q3W) or SOX for 3 cycles pre/post D2 surgery, then R plus C (SOXRC) or S-1 (SOX) up to 17 cycles per investigator's choice...Preoperative grade ≥3 treatment-emergent adverse events occurred at rates of 36.3% (SOXRC) and 16.3% (SOX). Conclusions The trial showed perioperative C combined with R and chemo significantly improved pCR compared to chemo alone with a tolerable safety profile for localized resectable G/GEJ adenocarcinoma."

Clinical • Metastases • P3 data • P3 data: top line • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology

ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. (ASCO 2023) - P3 | "Investigators selected an appropriate adjuvant chemotherapy (tegafur/gimeracil/oteracil [S-1] therapy or capecitabine plus oxaliplatin [CapeOX] therapy) for each patient, and thereafter patients were randomly assigned (1:1) to the N+C or placebo plus chemotherapy (P+C) arm, using the allocation factors of country and disease stage. The ATTRACTION-5 study of N+C vs P+C in patients with pStage III G/GEJ cancer after D2 or more extended gastrectomy did not meet the primary endpoint of RFS. The safety profile in the ATTRACTION-5 study was consistent with its known safety profile. Clinical trial information: NCT03006705."

Clinical • P3 data • Gastric Cancer • Gastrointestinal Cancer • Immune Modulation • Oncology

Synchronous Multifocal Intraductal Tubulopapillary Neoplasm of the Pancreas Treated with Total Pancreatectomy: A Case Report. (PubMed, Surg Case Rep) - "We describe an extremely rare case of a synchronous multifocal ITPN. The noncontiguous distribution observed in this case raises the possibility of multicentric development, although alternative mechanisms cannot be excluded. Further case accumulations and molecular analyses are required to clarify the pathogenesis of this disease and establish optimal treatment strategies."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction (clinicaltrials.gov) - P2 | N=116 | Active, not recruiting | Sponsor: Xijing Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • PD-L1

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study. (PubMed, Lancet) - P3 | "Neoadjuvant serplulimab plus SOX followed by adjuvant serplulimab significantly improved event-free survival and demonstrated a better safety profile compared with neoadjuvant and adjuvant SOX in PD-L1-positive, resectable gastric or gastro-oesophageal junction adenocarcinoma. Extended follow-up for the overall survival data is warranted to confirm a survival advantage of this perioperative strategy with a chemotherapy-sparing adjuvant component for this indication."

Journal • P3 data • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • PD-L1

Assessing the efficacy of adjuvant chemotherapy in patients with T3N0 gastric cancer. (PubMed, Eur J Surg Oncol) - "In patients with T3N0 stage after surgery, the chemotherapy group demonstrated OS and RFS similar to surgery-only group. Therefore, the benefit of adjuvant chemotherapy in patients with T3N0 gastric cancer remains uncertain."

Journal • Gastric Cancer • Oncology • Solid Tumor

LBA: Short-term results of a phase III trial to confirm efficacy of preoperative S-1 plus oxaliplatin added to the upfront surgery followed by postoperative chemotherapy containing S-1 for patients with clinical stage III gastric cancer(JCOG1509) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Surgery • Gastric Cancer • Oncology • Solid Tumor

A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01. (ASCO 2024) - P3 | " ARTEMIDE-Biliary01 (NCT06109779) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig IV every three weeks versus placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1 [tegafur/gimeracil/oteracil] or gemcitabine/cisplatin) as adjuvant treatment in patients with BTC after curative intent resection. Additional endpoints include progression-free survival following recurrence, patient-reported tolerability, and safety. Enrollment has begun, and approximately 200 sites will be recruiting globally across Asia, Australia, Europe, North America, and South America."

Clinical • P3 data • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TIGIT

Sintilimab combined with short-course intensified chemotherapy regimen nab-POF in the treatment of metastatic gastric cancer (FDZL-GC002): A single-arm, phase 2 trial. (ASCO 2026) - P2 | " Eligible patients (pts) received Sin (200mg IV), nab-paclitaxel (125mg/m²), oxaliplatin (85mg/m²), and fluorouracil (2400mg/m² as a 48-hour infusion) (plus trastuzumab for HER2+ pts) Q2W. After 6 cycles, pts without disease progression received maintenance treatment (capecitabine + Sin)... Sin plus short-course intensified chemotherapy regimen Nab-POF demonstrates high response and CR rate, and remarkable long-term effects. This approach may represent a feasible first-line treatment strategy, warranting further evaluation in randomized trials."

Metastases • P2 data • Gastric Cancer • Oncology • Solid Tumor • HER-2

A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarcinoma (BR + UR-LA) (CSGO-HBP-008). (PubMed, Surg Today) - "GSRT is a safe and effective treatment for patients with locally advanced PDAC."

Journal • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial. (ASCO-GI 2025) - P3 | "Intraperitoneal and intravenous paclitaxel plus S-1 significantly improved the overall survival compared to intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis, with manageable toxicity."

Clinical • P3 data • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

S-1 plus serplulimab consolidation after concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a phase II trial (ESMO 2026) - No abstract available

Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Efficacy and safety of radiotherapy in combination with S-1 and nimotuzumab in elderly patients with esophageal cancer: a prospective single-arm study (ESMO 2026) - No abstract available

Clinical • Combination therapy • Esophageal Cancer • Oncology

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015). (PubMed, Ann Surg Oncol) - "This study found that GA and GS are viable neoadjuvant treatment regimens in R/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved."

Journal • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CA 19-9

Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6). (ASCO 2026) - P3 | "Previously untreated patients with HER2-negative unresectable advanced or recurrent G/GEJ cancer were randomized 1:1 to receive NIVO 360 mg every 3 weeks, IPI 1 mg/kg every 6 weeks in addition to Chemo (S-1 plus oxaliplatin [SOX] or capecitabine plus oxaliplatin [CAPOX]) or Chemo alone... In ATTRACTION-6 study, NIVO + IPI + Chemo did not improve OS compared with Chemo as 1L treatment for patients with HER2-negative unresectable advanced or recurrent G/GEJ cancer. Although toxicity increased with the addition of NIVO and IPI, no new safety signals were observed."

Clinical • Metastases • P3 data • Gastroenterology • Gastrointestinal Disorder • Oncology • Solid Tumor • HER-2 • PD-L1

SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). (PubMed, Eur J Cancer) - "SLOG did not demonstrate superiority in PFS over mFOLFIRINOX, and mFOLFIRINOX therefore remains as one of the preferred first-line standards. Given its lower incidence of severe neutropenia and its convenience with oral S-1, SLOG may warrant further investigation in selected Asian patients with advanced PDAC."

Journal • P2 data • Neutropenia • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HRD

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results (ESMO Asia 2024) - P3 | "Methods Participants (pts) received D 1500 mg (first infusion: 60 min; subsequent infusions: 30 min) with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin, carboplatin, cisplatin (cis), tegafur-gimeracil-oteracil (S-1), cis + S-1, or cis + nab-paclitaxel). Conclusions No difference in infusion-related safety between 30 and 60 min infusion time was observed. No new safety signals were seen with the addition of D to other chemotherapy regimens beyond TOPAZ-1 regimens."

Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study. (ASCO 2026) - P=N/A | "After 6 induction cycles, oxaliplatin was discontinued in both cohorts, and maintenance therapy consisted of S-1/capecitabine plus PD-1 inhibitor, with or without continued fruquintinib... This initial analysis from the biomarker-oriented MGC-FLORA study suggests that the addition of fruquintinib to first-line immunochemotherapy may improve clinical efficacy in advanced G/GEJ adenocarcinoma. Consistent trends toward prolonged PFS were observed in both the overall and propensity score–matched populations, supporting a potential therapeutic benefit of fruquintinib. These findings warrant further validation in randomized trials and integrated biomarker analyses."

Biomarker • Clinical • IO biomarker • Metastases • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Oncology • CLDN18

Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial. (ASCO-GI 2026) - P3 | "The addition of oxaliplatin to S-1 chemotherapy significantly improved both overall survival and disease-free survival in patients with stage II-III gastric or GEJ adenocarcinoma. SOX regimen should be considered as a standard adjuvant treatment option for this patient population following D2 gastrectomy."

Clinical • P3 data • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer. (PubMed, J Immunother Cancer) - "This study met its primary efficacy and safety endpoints. The combination of neoadjuvant durvalumab plus DOS, followed by surgery and adjuvant durvalumab plus S-1 chemotherapy, warrants further investigation in a phase 3 trial for Asian patients with LAGC."

Journal • P2 data • Febrile Neutropenia • Gastric Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor